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Several aminocyclitol-aminoglycoside antibiotics have been studied by tandem mass spec-
trometry. Glycosidic bond cleavages were the major reactions in the low energy collisionally
activated decomposition (CAD) of the protonated antibiotics. Only the glycoside residing on
the C6™O of the 2-deoxystreptamine was observed to undergo significant decomposition at the
C2™C3 and O™C1 bonds. The comprehension of the CAD of known aminoglycosides aided in
the identification of an unknown impurity in tobramycin. The unknown compound was
initially detected by reverse phase high-performance liquid chromatography following dini-
trofluorobenzene derivatization of the amino groups. The molecular weight of the dinitroben-
zene derivative measured by LC mass spectrometry (MS) led to the detection of two isomeric
impurities in tobramycin by LC-MS using an amino column. Their CAD spectra were
subsequently acquired by LC-MS/MS. One of the two compounds was determined to be a
known compound, 60-O-carbamyltobramycin with the carbamyl group substituted on the
glycoside residing on the C6™O of 2-deoxystreptamine. The fragmentation pattern of the other
compound was interpreted as that the unknown was also a carbamyltobramycin. The
carbamyl group was, however, substituted on 2-deoxystreptamine. It was speculated that the
carbamyl group was substituted at the C1 amino group. This compound, to our knowledge,
has not been reported before. (J Am Soc Mass Spectrom 2000, 11, 200–209) © 2000 American
Society for Mass Spectrometry
Aminoglycoside antibiotics have activity againsta wide spectrum of aerobic bacteria [1]. Despitetheir nephro- and ototoxicity [2], aminoglyco-
side antibiotics are important clinically due to their
effectiveness against certain bacterial infections, such as
pneumonia and septicemia, for which other antibiotics
are less effective.
The application of mass spectrometry in the study of
aminoglycoside antibiotics has echoed the development
of ionization techniques in mass spectrometry. The
early studies using electron impact ionization [3, 4]
yielded results indicative of mixed electron ionization
(EI) and chemical ionization (CI) processes as the (M 1
H)1 ions were present in the EI spectra of most of the
aminoglycosides. Typically, extensive glycoside frag-
mentations took place in addition to the glycosidic bond
cleavages.
With the invention of various soft ionization tech-
niques, the aminoglycoside molecules have been ana-
lyzed by CI [5], fast atom bombardment (FAB) [6], and
most recently by electrospray ionization (ESI) [7]. With
the exception of CI, these ionization methods, without
coupling to MS/MS techniques, produced largely mo-
lecular species with very few fragments to shed light on
their structures.
McLaughlin et al. [8] recently acquired the collision-
ally activated decomposition (CAD) spectra of the (M 1
2H)21 ions of some aminoglycoside antibiotics to de-
velop a specific LC-MS/MS method for the detection of
these antibiotics in bovine kidney tissues. The product
ions reported were primarily formed from the glyco-
sidic bond cleavages.
We report here the CAD of the (M 1 H)1 ions of
several aminoglycosides produced by ESI. We also
report the application of the fragmentation patterns
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generalized in this study, in the differentiation of ami-
noglycoside isomers, and in the structure determination
of an unknown aminoglycoside in a tobramycin sample
at a trace level without prior separation.
Experimental
Chemical
The tobramycin sample, from which the unknown
compound was identified, was obtained from Auto-
matic Liquid Packaging, Inc. The 60-O-carbamylkana-
mycin B sample was obtained from Biogal Pharmaceu-
tical Works, Debrecen, Hungary. The Gentamicin
sample was acquired from U.S.P.C., Rockville, MD
(Cat# 28900). The 60-O-carbamyltobramycin sample
with 56% purity was provided by ChongQing Daxin
Pharmaceutical, China. Kanamycin A, sisomicin, netil-
micin, and ribostamycin samples were purchased from
SIGMA Chemical, St. Louis.
HPLC
The HPLC instrument used for the analysis was a
Hewlett Packard 1090 equipped with a photodiode
array detector. An Astec (Registered trademark of Ad-
vanced Separation Technologies) NH2 polymer column
(250 3 4.6 mm, 5 mm) and a water/acetonitrile gradient
were used for the separation. The gradient started with
15% of water for 2 min. The percentage of water was
increased to 70% in the next 30 min. The detector was
set to monitor at 196 nm, and the flow rate was 1
mL/min. The HPLC sample was prepared by mixing 1
aliquot of saturated tobramycin solution in water with 3
aliquots of water. The injection volume of the resulting
solution was 15 mL.
ESI-MS and ESI-MS/MS
The experiments were performed on a Quattro (Regis-
tered trademark of Micromass) triple quadrupole mass
spectrometer equipped with an electrospray ionization
source. The samples were introduced into the electros-
pray ionization source by a Harvard infusion pump at a
typical flow rate of 1 mL/min with no nebulizing gas
flow. The mass resolution of the quadrupole analyzer
was typically set to obtain unit resolution. The samples
were analyzed in 50% methanol at a concentration level
of 0.1 mg/mL.
For ESI-MS/MS experiments, the precursor ions pro-
duced by the ESI source were selected by the first
quadrupole analyzer and were subjected to collisional
activation with argon gas in the second quadrupole
(collision cell). The resulting product ions were ana-
lyzed by the third quadrupole. The precursor beam
suppression was typically 75%.
LC-MS and LC-MS/MS
The LC-MS experiments were performed on the Fisons
Quattro triple quadrupole mass spectrometer coupled
with an HP1090 HPLC. The HPLC eluant was split by a
Valco (Registered trademark of Valco Instruments)
valve. The flow to the ESI source of the mass spectrom-
eter through a fused silica capillary of 1 m length and 75
mm i.d. was limited to approximately 10% of the LC
flow. The ion source temperature was raised to 120 °C
from the 80 °C for typical ESI experiments to accommo-
date the high liquid flow into the ion source. The ESI
was also assisted with nebulizing gas of approximately
10 L/min. The mass spectrometer was tuned so that soft
ionization conditions were achieved to observe the
molecular species. The cone voltage was set to a low 25 V.
The LC-MS/MS was performed in the same fashion
as the ESI-MS/MS experiments except that the samples
were introduced into the mass spectrometer by the
HPLC. For the LC-MS/MS/MS experiment, the precur-
sor ion was dissociated by the ESI source operating at
high cone voltage to produce the first generation prod-
uct ion which was selected by the first quadrupole as
the precursor ion of an MS/MS experiment. The CAD
spectrum of the first generation product ion was then
acquired as if it was an LC-MS/MS experiment.
In both LC-MS/MS and LC-MS/MS/MS experi-
ments, the product ion intensities were extremely low.
The resolution settings on the third quadrupole were
set so that maximum sensitivity was obtained. Thus, the
isotopic ions of the product ions were not well sepa-
rated.
Results and Discussion
CAD of Protonated Aminoglycosides
A total of 10 trisaccharide aminoglycoside antibiotics
(Figure 1) were included in this study. They were all O4,
O6-disubstituted 2-deoxystreptamines with the excep-
tion of ribostamycin which had a glycoside substituted
on O5. The CAD spectra of the protonated tobramycin,
sisomicin, and ribostamycin are shown in Figure 2 as
examples. The product ions and their relative abun-
dances of all compounds are tabulated in Table 1. The
dissociations of the antibiotics in the CAD experiment
occurred dominantly at the glycosidic linkages leading
to the formation of individual glycoside ions, 2-deoxy-
streptamine ion, and ions containing two glycosides.
Ring opening cleavage occurred only to the glycoside
unit on the C6™O of 2-deoxystreptamine. The structures
of the major ions are proposed in Scheme 1 using
tobramycin as the example. For convenience of discus-
sion, the three rings in the structures were letter coded
as A, B, and C. The center ring (ring B), 2-deoxy-
streptamine, was common for all compounds studied
here. Ring A referred to the glycoside linked to the
C6™O of the 2-deoxystreptamine, and ring C referred to
the glycoside on the C4™O of the 2-deoxystreptamine.
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For ribostamycin, which had a glycoside on the C5™O of
ring B, ring A referred to the glycoside on the C5™O of
2-deoxystreptamine.
The product ions of the protonated antibiotics were
also letter coded. The lettering denoted the part of the
structure from which they were derived in the CAD.
For instance, ions from the three individual rings were
called (A 2 H2O), B, and (C 2 H2O) because rings A
and C appeared in dehydrated forms, whereas ring B
was observed as protonated 2-deoxystreptamine. Simi-
larly, if two rings were found in an ion, the ion was then
coded by two letters, such as AB and BC, denoting the
two constituent rings. The BX, BCX, and (A 2 X) ions
represented the product ions of ring A fission with and
without the prior loss of ring C.
The letter coding of the product ions was expanded
in Table 1 to cover the ions formed from water or
ammonia losses. For example, the (BC-18/17) ion re-
ferred to the ion formed from the ion BC through a loss
of water or ammonia molecule. If both water loss and
Figure 1. The structures of the aminocyclitol-aminoglycoside antibiotics studied.
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ammonia loss were present, both ions were listed in the
table.
The transitions shown in Scheme 1 were the major
routes for the formation of the product ions. The
individual glycoside ions could also be formed from
other intermediates. All transitions in Scheme 1 were
confirmed by parent ion scans.
Netilmicin, and 60-O-carbamyltobramycin were
modified sisomicin and tobramycin, respectively (for
structures, see Figure 1). The mass shifts reflecting the
changes in the product ions containing the modified
structural moieties supported the structural assign-
ments of the product ions in Scheme 1. For instance, the
AB ion of 60-O-carbamyltobramycin which contained
the carbamyl group, was found at m/z 367 versus m/z
324 for the AB ion of tobramycin. The BX, B, and (C 2
H2O) ions of 60-O-carbamyltobramycin were found to
have the same m/z values as the counterpart ions of
tobramycin at 205, 163, and 145, respectively.
Netilmicin is a sisomicin ethylated at the C1™N of the
2-deoxystreptamine. All product ions of netilmicin con-
taining ring B had m/z values of 28 u higher than the
corresponding ions produced from sisomicin. For ex-
ample, the m/z values of the B and BX ions were found
at 199 and 233 corresponding to a shift of 28 u from the
m/z values of B and BX ions of sisomicin at 163 and 205.
The (C 2 H2O) and (A 2 H2O) ions were found at m/z
127 and 160 for both netilmicin and sisomicin (Table 1).
The collision induced fragmentation of the glycoside
residing on the C6™O/C5™O of the 2-deoxystreptamine
ring involved the fission of C1™O and C2™C3 bonds of
the A ring, leading to the formation of BX, BCX, and
(A 2 X) ions. The (A 2 X) ion was formed from the
part of the molecule complementary to that from which
the BX and BCX ions were made. The relative abun-
dance of the (A 2 X) ion appeared to be dependent
upon the ability of ring A to compete for the protona-
tion. The garosamine containing compounds, such as
sisomicin, netilmicin, and the gentamicins, generated
more abundant (A 2 X) ions (m/z 118) than the nonga-
rosamine containing molecules, e.g., tobramycin and
kanamycin A (m/z 120).
The competitiveness of this reaction to the glycosidic
bond cleavage varied. For tobramycin and kanamycin,
Figure 2. The CAD spectra of the (M 1 H)1 ions of (a) tobramycin, (b) sisomycin, and (c)
ribostamycin. The precursor ion beam suppression for the experiments was approximately 75%.
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the BX ion (m/z 205) from ring A opening was one of the
major ions (Table 1). The BCX and BX ions were only
weakly formed from the gentamicin molecules (less
than 5% relative abundance). Ribostamycin produced a
BX ion at m/z 205 of approximately 1%.
The relative abundances of the three ions produced
from the two glycosides and 2-deoxystreptamine were
strongly influenced by the relative basicity of the two
glycosides with regard to 2-deoxystreptamine. The A
rings for tobramycin, kanamycin, and ribostamycin
were the least basic glycoside, the (A 2 H2O) ions were
observed in low relative abundances. The abundance of
the (A 2 H2O) ion was 7% for tobramycin, and 1% for
ribostamycin, respectively. The (A 2 H2O) ion and
(C 2 H2O) ion of kanamycin had the same m/z value of
162. The two ions accounted for 20% relative abun-
dance. The major contribution was probably from the
(C 2 H2O) ion.
The three gentamicin molecules, netilmicin, and si-
somycin all had garosamine on the C6™O of 2-deoxy-
streptamine. Garosamine contained a secondary amine
group making it more basic than the other glycoside
and 2-deoxystreptamine. The (A 2 H2O) ion was the
most abundant among the three ions produced from the
three rings of netilmicin, sisomicin, and gentamicin C1a.
Gentamicin C1 was an exception. The (C 2 H2O) ion
was the most abundant among the three ions. However,
the C ring of gentamicin C1 also contained a secondary
amine with comparable basicity to garosamine.
Sisomicin and netilmicin were the only pair contain-
ing a double bond in the glycoside on the C4™O of
2-deoxystreptamine. These two compounds produced
the most extensive fragmentation in the CAD of their
(M 1 H)1 ions. The ions formed from the loss of water
and losses of both water and ammonia were abundant.
The BC and BCX ions of sisomicin with m/z values of
289 and 331, respectively, also produced intense water
and ammonia losses. The AB ion of sisomicin at m/z 322,
however, did not yield any water or ammonia losses.
Apparently, the unsaturation on ring C contributed to
the propensity to lose water and/or ammonia.
The simplicity in the CAD of aminoglycosides was in
sharp contrast with the extensive fragmentations under
EI described by Daniels et al. [3]. This was perhaps not
surprising because the majority of the fragment ions in
the EI/CI spectra were the products of radical molecu-
lar species instead of the protonated molecular species.
The more dominant ion series in EI arising by cleavage
of the C1™C2 bonds of the respective sugar units fol-
lowed by fission of the C5™O bond with hydrogen
transfer [3, 11] were absent in the CAD spectra of the
(M 1 H)1 ions. The alternative fragmentation of the
glycosidic unit on the C6™O of 2-deoxystreptamine, i.e.,
the cleavage of the C1™O and C2™C3 bonds of the A ring,
was the more prominent glycosidic ring cleavages for
the (M 1 H)1 ions.
In the CAD of the protonated aminoglycosides, the
protonated 2-deoxystreptamine was shown by parent
ion scan to form from the protonated molecular speciesTa
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or from the AB ion by simple glycosidic cleavages. In EI,
the protonated 2-deoxystreptamine was reported to
form from the intermediate derived from the C1™C2 and
C5™O bond cleavages of the A ring [3].
As discussed previously [8] the product ions derived
from the glycosidic cleavages were also the major ions
in the CAD of the (M 1 2H)21 ions of tobramycin,
gentamicinC1a, gentamicinC2, and gentamicinC1. The AB
ion was typically the most abundant followed by the
individual glycoside ions. The BX ion at m/z 205 was
listed for tobramycin with a relative abundance of 38%.
The BX ions were not listed for the gentamicins, pre-
sumably due to their low abundances. In our experi-
ments, the BX ions were produced from the gentam-
icins, but in low abundances (see Table 1). The (M 1
H)1 ions discussed in this study showed more or less
the same fragmentation pattern. Therefore, the number
of charges in the precursor ions did not seem to affect
their dissociation pathways in CAD significantly.
Structure Elucidation for an Unknown Impurity in
Tobramycin
Tobramycin [9, 10] was one of several aminoglycoside
antibiotics purified from the nebramycin complex [11,
12] elaborated by Streptomyces tenebrarius. Its isolation
from the complex involved extraction from the fermen-
tation broth using ion exchange resin and further chro-
matographic purification [11].
An unknown impurity was detected when tobramy-
cin samples were analyzed by reverse phase HPLC
following derivatization with dinitrofluorobenzene
[13]. The molecular weight of the derivatized com-
pound was measured as 1174 (the m/z value for the
derivatized unknown compound was measured by
negative ion LC-MS at 1173). Because the substitution of
each amino group by a dinitrobenzene group during
the derivatization added 166 u to the molecule, the
possible molecular weight of the unknown compound
was limited to 1008, 842, 676, 510, or 344, corresponding
to molecules containing one to five derivatizable amino
groups, respectively.
The HPLC analysis of the underivatized tobramycin
sample using an amino column and mass spectrometric
detection with ESI identified two compounds of the
molecular weight 510 (Figure 3). The two compounds
nearly coeluted with tobramycin, with one on the
leading edge (RT ; 11.4 min) and the other on the
tailing edge (RT ; 14.3 min) of the tobramycin peak.
The molecular weight implied that both compounds
Scheme 1
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had four derivatizable amino groups. No compounds
having the other possible molecular weights were ob-
served. Although the two compounds were not sepa-
rated from tobramycin, they were sufficiently separated
from each other for the independent acquisition of the
CAD spectra of their (M 1 H)1 ions (Figure 4).
A few low mass ions found in the CAD of tobramy-
cin were also observed in dissociations of the two
unknown compounds upon collisional activation. The
m/z 145, 163, and 205 ions corresponding to the (C 2
H2O), B, and BX ions of tobramycin, respectively, were
produced from the earlier eluting compound, and the
m/z 145 and 163 ions (low abundance) were observed to
form from the second compound. These observations,
and the fact that they nearly coelute with tobramycin,
suggested that they were tobramycin-related com-
Figure 3. The LC-MS analysis of tobramycin using an amino column.
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pounds. Their molecular weight of 510 was 43 u higher
than that of tobramycin, indicating a carbamyl group as
the likely modifying moiety. A good match between the
CAD spectrum of 60-O-carbamyltobramycin and the
CAD spectrum of the early eluting compound sug-
gested the compound was 60-O-carbamyltobramycin.
The other compound, presumably also a carbamyl
tobramycin, must have the carbamyl group substituted
at a different location. The (C 2 H2O) ion was abun-
dantly formed, suggesting that ring C was the same as
that of tobramycin. Because the usually abundant B ion
at m/z 163 was only weakly formed, 2-deoxy-
streptamine was suspected to be the site of modifica-
tion. Indeed, an ion at m/z 206, 43 u higher than 163, was
abundantly formed. Confirmation of the B ring modifi-
cation was also reflected in the mass shift of the BX ion
to m/z 248.
There were three possible functional groups, two
amino groups and one hydroxyl group on 2-deoxy-
streptamine, for substitution by the carbamyl group.
The hydroxyl group was ruled out because the un-
known compound had four dinitrofluorobenzene deri-
vatizable amino groups, one less than tobramycin.
Thus, the carbamyl group was residing on one of the
two amino groups on 2-deoxystreptamine, preventing
the amino group from dinitrofluorobenzene derivatiza-
tion.
The mass shifts for the product ions of the unknown
with respect to the masses of tobramycin product ions
followed the exact same pattern for the mass shifts of
netilmicin product ions with respect to the masses of
sisomicin product ions. Netilmicin is an ethyl-substi-
tuted sisomicin having the ethyl substitution on the
C1™NH2 group of 2-deoxystreptamine. All 2-deoxy-
streptamine-containing product ions of netilmicin were
mass shifted by 28 u from the masses of the correspond-
ing ions of sisomicin. For example, the B, AB, and BX
ions of sisomicin were found at m/z 163, 322, and 205,
respectively, whereas the same three ions of netilmicin
were observed at 191, 350, and 233, respectively. The
(A 2 H2O), (C 2 H2O), and the (A 2 X) ions had m/z
values of 160, 127, 118, respectively, for both netilmicin
and sisomicin. For the unknown compound, mass shifts
(with respect to the m/z values of corresponding tobra-
mycin ions) also occurred for the B and BX ions, but not
for the (C 2 H2O) ion (Figure 4b).
Figure 4. The CAD spectra of the (M 1 H)1 ions of the two impurity compounds.
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Further evidence supporting the structure assign-
ment came from the LC-MS/MS/MS experiments. The
m/z 248 ion of the unknown was a product of carbamyl
substitution on the 2-deoxystreptamine of the m/z 205
ion of tobramycin. The CAD spectra of the ESI source
produced m/z 248 (from the unknown) and m/z 205 ions
(from tobramycin), are shown in Figure 5. The m/z 248
ion produced the m/z 205 ion by losing 43 u. The m/z 248
ion also lost 17 u to produce the m/z 231 ion, indicating
strongly the presence of a carbamyl group in the m/z 248
ion (see Scheme 2). Furthermore, the part (below m/z
205) of the CAD spectrum of the m/z 248 ion contained
all major ions in the CAD spectrum of the tobramycin
m/z 205 ion (compare Figure 5a, b). This indicated that
the m/z 205 ion formed from the m/z 248 ion via a loss of
the carbamyl group had the same structure as the m/z
205 ion of tobramycin.
Although the fragmentation of the m/z 248 ion pro-
duced evidence implicating carbamyl substitution on
the 2-deoxystreptamine, no discriminating evidence
was produced to enable the differentiation of the pos-
sible two isomers with the carbamyl group on different
amino groups. The carbamyl group was too labile
compared with the 2-deoxystreptamine ring structure.
The m/z 248 ion decomposed first by shedding the
carbamyl group to produce the m/z 205 ion. The posi-
tioning of the carbamyl group on 2-deoxystreptamine,
therefore, had no influence on the fragmentation of
2-deoxystreptamine itself.
The first reported substitution on the 2-deoxy-
streptamine in nature was the acylation at the C1 amino
group by L(2)-g-amino-a-hydroxybutyric acid (L-
HABA) [14]. The L-HABA modified ribostamycin
named butirosin was shown to be a better antibiotic
than ribostamycin in that it was effective against ribos-
tamycin-kanamycin resistant bacteria. This discovery
sparked an array of efforts to modify the existing
aminoglycoside antibiotics to improve their properties
[15–17]. Both synthetic and biological methods were
explored, and both achieved selective acylation on the
Figure 5. The CAD spectra of the m/z 248 ion of the unknown compound (a) and the m/z 205 ion of
tobramycin (b). The spectra were acquired by LC-MS/MS/MS experiments. The m/z 248 and 205 ions
were produced from their corresponding precursor ions by source-induced fragmentation inside the
electrospray ionization source.
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C1 amino group on 2-deoxystreptamine. Thus, very
likely the carbamyl substitution in the unknown struc-
ture was also on the C1 amino group (below).
Conclusion
The low energy CAD of protonated aminoglycosides
produced a simple set of product ions. The dominant
product ions were derived from the glycosidic bond
cleavages. Ring opening reaction only occurred at the
glycoside (A ring) on the C6™O of 2-deoxystreptamine
involving the C1™C2 and the C1™O bond cleavages.
Two isomeric carbamyl tobramycins were uncovered
in tobramycin samples by LC-MS. The LC-MS/MS data
enabled the identification of one compound as 60-O-
carbamyltobramycin, which was known. The other
compound was identified as carbamyl tobramycin with
the carbamyl group substituted on 2-deoxystreptamine.
It was speculated that the carbamyl substitution was on
the C1 amino group because acylation was observed in
nature only to occur on the C1 amino group for amino-
glycoside antibiotics, and because the C1 amino group
was also the more reactive of the two amino groups of
2-deoxystreptamine as shown in synthetic products.
Unambiguous determination of the carbamyl substitu-
tion position can be achieved by high resolution NMR
analysis, should sufficient quantity of pure material be
available. Obtaining sufficient pure material for NMR
study, however, is beyond the scope of this study.
LC-MS and LC-MS/MS have been shown to be
extremely useful in the detection and structure deter-
mination of trace level impurities in glycoside antibiot-
ics without prior separation. These extremely hydro-
philic and thermally labile compounds can be analyzed
directly by ESI-based LC-MS methods. The trace level
impurities do not have to be completely separated from
the major component by HPLC.
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